Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.30
-0.14 (-0.68%)
At close: Jul 3, 2025, 1:00 PM
20.50
+0.20 (0.99%)
After-hours: Jul 3, 2025, 4:28 PM EDT
Genmab Revenue
Genmab had revenue of $715.00M in the quarter ending March 31, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to $3.23B, up 25.43% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.23B
Revenue Growth
+25.43%
P/S Ratio
3.90
Revenue / Employee
$1,204,661
Employees
2,682
Market Cap
12.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GMAB News
- 4 days ago - Genmab Announces Changes to its Executive Committee - GlobeNewsWire
- 5 days ago - Completion of Share Buy-back Program - GlobeNewsWire
- 12 days ago - Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One - Seeking Alpha
- 12 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 18 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 18 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 20 days ago - Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - Business Wire
- 23 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire